Print
Email
Print Edition Stories
Rib-X Pharmaceuticals Inc. has filed a registration statement to go public, the New Haven, Conn.-based biotech said in a news release this morning.
The company did not detail the number of shares, nor the anticipated price of the shares, for the proposed initial public offering of its common stock. The offering was supported by Deutsche Bank Securities as sole book-running manager, with co-managers William Blair & Co., Lazard Capital Markets and Needham & Co.
Rib-X develops antibiotic treatments using a ribosome-based platform. The company was founded in 2001 by Yale University colleagues Peter Moore, William Jorgensen and Thomas Steitz, winner of a portion of the 2009 Nobel Prize in Chemistry for his work describing the structure and function of the ribosome.
In July, Rib-X formed a partnership with French biotech giant Sanofi (NYSE: SNY) to develop antibiotics to fight superbugs. The deal has the potential to bring more than $740 million to Rib-X; as of two weeks after the partnership announcement in July, Rib-X landed a $9 million milestone payment from Sanofi.
In September, the company made some internal appointments, promoting Erin Duffy to chief scientific officer of the company and Jarrod Longcor to vice president, corporate development.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
